Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CuraGen Corporation
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Females with confirmed breast cancer
Age ≥ 18 years
Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2
Locally advanced or metastatic disease who have received at least two prior chemotherapeutic regimens for breast cancer, as follows:
* At least one regimen must have been for locally advanced or metastatic disease
* Subject must have received an anthracycline, a taxane, and capecitabine in any combination unless the subject was intolerant to or not a candidate for any of these agents
* Hormonal therapy, biologic therapy (such as trastuzumab or bevacizumab), or immunotherapy do not count as one of the 2 regimens
* Subjects with HER2/neu overexpressing tumors must have been treated with trastuzumab except in situations where the subject was intolerant to or not a candidate for trastuzumab
Documented progressive disease within 6 months of the last regimen
Adequate bone marrow, renal and liver function
Signed informed consent
You may not be if
Chemotherapy, radiation, hormonal therapy, or bevacizumab within two weeks, or trastuzumab or investigational therapy within three weeks before treatment start
Neuropathy \> NCI-CTCAE Grade 1
Active brain metastases.
New York Heart Association class III or IV heart disease
Unstable angina
Uncontrolled arrhythmia
A marked baseline prolongation of QT/QTc interval
Pregnant or breast-feeding women, and women of childbearing age and potential who are not willing to use effective contraception
